Bio-Techne Corp
Fermé
SecteurSoins de santé
57.69 4.97
Résumé
Variation du prix de l'action
24h
Min
56.94
Max
58.08
Revenu | 13M 51M |
|---|---|
Ventes | 16M 311M |
P/E Moyenne du Secteur | 80.243 49.712 |
BPA | 0.53 |
Rendement du dividende | 0.59 |
Marge bénéficiaire | 16.392 |
Employés | 3,100 |
EBITDA | 21M 99M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +3.37% upside |
Rendement du dividende Moyenne du Secteur | 0.59% 2.36% |
|---|---|
Prochains Résultats | 5 août 2026 |
Date du Prochain Dividende | 28 août 2026 |
Capitalisation Boursière | 230M 8.8B |
|---|---|
Ouverture précédente | 52.72 |
Clôture précédente | 57.69 |
Sentiment de l'Actualité
By Acuity
76%
24%
301 / 342 Classement par Healthcare
Bio-Techne Corp Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.